{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:31:58Z","timestamp":1795026718371,"version":"4.10.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014261","name":"National Institute for Health Care Management Foundation","doi-asserted-by":"publisher","award":["K23 DK122104"],"award-info":[{"award-number":["K23 DK122104"]}],"id":[{"id":"10.13039\/100014261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P500PM_210866"],"award-info":[{"award-number":["P500PM_210866"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prior studies suggest a link between metabolic dysfunction-associated steatotic liver disease (MASLD) and incident arrhythmias, including atrial fibrillation (AF). However, robust data are lacking from cohorts with liver histology, which remains the gold standard for staging MASLD severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based cohort included all Swedish adults with histologically-confirmed MASLD and without prior cardiac arrhythmias (1966\u20132016; n\u2009=\u200911,206). MASLD was defined from prospectively-recorded histopathology, and characterized as simple steatosis, non-fibrotic steatohepatitis (MASH), non-cirrhotic fibrosis, or cirrhosis. MASLD patients were matched to\u2009\u2264\u20095 controls without MASLD or arrhythmias, by age, sex, calendar year and county (n\u2009=\u200951,856). Using Cox proportional hazards modeling, we calculated multivariable-adjusted hazard ratios (aHRs) for incident arrhythmias (including AF, bradyarrhythmias, other supraventricular arrhythmias, ventricular arrhythmias\/cardiac arrest).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a median follow-up of 10.8\u00a0years, incident arrhythmias were confirmed in 1351 MASLD patients (10.3\/1000 person-years [PY]) and 6493 controls (8.7\/1000PY; difference\u2009=\u20091.7\/1000PY; aHR\u2009=\u20091.30, 95%CI 1.22\u20131.38), and MASLD patients had significantly higher rates of incident AF (difference\u2009=\u20090.9\/1000PY; aHR\u2009=\u20091.26, 95%CI 1.18\u20131.35). Rates of both overall arrhythmias and AF were significantly elevated across all MASLD histological groups, particularly cirrhosis (differences, 8.5\/1000PY and 5.3\/1000PY, respectively). In secondary analyses, MASLD patients also had significantly higher rates of incident ventricular arrhythmias\/cardiac arrest (aHR\u2009=\u20091.53, 95%CI 1.30\u20131.80), bradyarrhythmias (aHR\u2009=\u20091.26, 95%CI 1.06\u20131.48), and other supraventricular arrhythmias (aHR\u2009=\u20091.27, 95%CI 1.00\u20131.62), compared to controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to matched controls, patients with biopsy-confirmed MASLD had modest but significantly higher incidence of cardiac arrhythmias, including AF, bradyarrhythmias, other supraventricular arrhythmias and ventricular arrhythmias\/cardiac arrest. Excess risk was observed across all stages of MASLD and was highest with cirrhosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-023-02070-5","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T10:02:24Z","timestamp":1702461744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Tracey G.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahim","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Roelstraete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"issue":"1","key":"2070_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431[publishedOnlineFirst:20160222]","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431[publishedOnlineFirst:20160222].","journal-title":"Hepatology"},{"issue":"11","key":"2070_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.annepidem.2007.05.013[publishedOnlineFirst:2007\/08\/31]","volume":"17","author":"LA Adams","year":"2007","unstructured":"Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17(11):863\u20139. https:\/\/doi.org\/10.1016\/j.annepidem.2007.05.013[publishedOnlineFirst:2007\/08\/31].","journal-title":"Ann Epidemiol"},{"issue":"3","key":"2070_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x[publishedOnlineFirst:20110530]","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274\u201385. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04724.x[publishedOnlineFirst:20110530].","journal-title":"Aliment Pharmacol Ther"},{"key":"2070_CR4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.043[publishedOnlineFirst:2020\/02\/07]","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043[publishedOnlineFirst:2020\/02\/07].","journal-title":"Gastroenterology"},{"issue":"5","key":"2070_CR5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085[publishedOnlineFirst:20170331]","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557\u201365. https:\/\/doi.org\/10.1002\/hep.29085[publishedOnlineFirst:20170331].","journal-title":"Hepatology"},{"issue":"10","key":"2070_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12565[publishedOnlineFirst:2019\/10\/05]","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2(10): e1912565. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12565[publishedOnlineFirst:2019\/10\/05].","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2070_CR7","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034[publishedOnlineFirst:20141201]","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148\u201355. https:\/\/doi.org\/10.1016\/j.jhep.2014.11.034[publishedOnlineFirst:20141201].","journal-title":"J Hepatol"},{"issue":"2","key":"2070_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jhep.2015.02.045[publishedOnlineFirst:2015\/03\/18]","volume":"63","author":"JL Mellinger","year":"2015","unstructured":"Mellinger JL, Pencina KM, Massaro JM, et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham heart study. J Hepatol. 2015;63(2):470\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.045[publishedOnlineFirst:2015\/03\/18].","journal-title":"J Hepatol"},{"issue":"8","key":"2070_CR9","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1097\/HJH.0b013e32833a7de6[publishedOnlineFirst:2010\/05\/15]","volume":"28","author":"P Salvi","year":"2010","unstructured":"Salvi P, Ruffini R, Agnoletti D, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the cardio-GOOSE study. J Hypertens. 2010;28(8):1699\u2013707. https:\/\/doi.org\/10.1097\/HJH.0b013e32833a7de6[publishedOnlineFirst:2010\/05\/15].","journal-title":"J Hypertens"},{"issue":"8","key":"2070_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/oby.21879[publishedOnlineFirst:2017\/07\/27]","volume":"25","author":"TG Simon","year":"2017","unstructured":"Simon TG, Bamira DG, Chung RT, et al. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity. 2017;25(8):1313\u20136. https:\/\/doi.org\/10.1002\/oby.21879[publishedOnlineFirst:2017\/07\/27].","journal-title":"Obesity"},{"issue":"3","key":"2070_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013[publishedOnlineFirst:2016\/05\/24]","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.013[publishedOnlineFirst:2016\/05\/24].","journal-title":"J Hepatol"},{"issue":"7","key":"2070_CR12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786[publishedOnlineFirst:20201009]","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375\u201382. https:\/\/doi.org\/10.1136\/gutjnl-2020-322786[publishedOnlineFirst:20201009].","journal-title":"Gut"},{"issue":"1","key":"2070_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367[publishedOnlineFirst:20170929]","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357. https:\/\/doi.org\/10.1002\/hep.29367[publishedOnlineFirst:20170929].","journal-title":"Hepatology"},{"key":"2070_CR14","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6):1388\u2013402. doi: https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004","DOI":"10.1016\/j.jhep.2015.11.004"},{"issue":"8","key":"2070_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2337\/dc16-0091[publishedOnlineFirst:20160523]","volume":"39","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Rigamonti A, Bonapace S, et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care. 2016;39(8):1416\u201323. https:\/\/doi.org\/10.2337\/dc16-0091[publishedOnlineFirst:20160523].","journal-title":"Diabetes Care"},{"issue":"2","key":"2070_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101416[publishedOnlineFirst:20221228]","volume":"49","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Csermely A, Taverna A, et al. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. Diabetes Metab. 2023;49(2): 101416. https:\/\/doi.org\/10.1016\/j.diabet.2022.101416[publishedOnlineFirst:20221228].","journal-title":"Diabetes Metab"},{"issue":"4","key":"2070_CR17","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14044[publishedOnlineFirst:2019\/01\/19]","volume":"39","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Dauriz M, Sandri D, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 2019;39(4):758\u201369. https:\/\/doi.org\/10.1111\/liv.14044[publishedOnlineFirst:2019\/01\/19].","journal-title":"Liver Int"},{"issue":"7","key":"2070_CR18","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/liv.14461[publishedOnlineFirst:2020\/04\/13]","volume":"40","author":"X Cai","year":"2020","unstructured":"Cai X, Zheng S, Liu Y, et al. Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. Liver Int. 2020;40(7):1594\u2013600. https:\/\/doi.org\/10.1111\/liv.14461[publishedOnlineFirst:2020\/04\/13].","journal-title":"Liver Int"},{"issue":"9816","key":"2070_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0140-6736(11)61514-6[publishedOnlineFirst:2011\/12\/15]","volume":"379","author":"GY Lip","year":"2012","unstructured":"Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(11)61514-6[publishedOnlineFirst:2011\/12\/15].","journal-title":"Lancet"},{"issue":"2","key":"2070_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057183[publishedOnlineFirst:2013\/03\/02]","volume":"8","author":"G Targher","year":"2013","unstructured":"Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE. 2013;8(2): e57183. https:\/\/doi.org\/10.1371\/journal.pone.0057183[publishedOnlineFirst:2013\/03\/02].","journal-title":"PLoS ONE"},{"issue":"11","key":"2070_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142937[publishedOnlineFirst:2015\/11\/17]","volume":"10","author":"AJ Karajamaki","year":"2015","unstructured":"Karajamaki AJ, Patsi OP, Savolainen M, et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study). PLoS ONE. 2015;10(11): e0142937. https:\/\/doi.org\/10.1371\/journal.pone.0142937[publishedOnlineFirst:2015\/11\/17].","journal-title":"PLoS ONE"},{"key":"2070_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005227","author":"MT Long","year":"2017","unstructured":"Long MT, Yin X, Larson MG, et al. Relations of liver fat with prevalent and incident atrial fibrillation in the Framingham heart study. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.005227.","journal-title":"J Am Heart Assoc"},{"key":"2070_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2015.12.023[publishedOnlineFirst:2016\/01\/02]","volume":"245","author":"MR Markus","year":"2016","unstructured":"Markus MR, Meffert PJ, Baumeister SE, et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: the study of health in Pomerania (SHIP). Atherosclerosis. 2016;245:123\u201331. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.12.023[publishedOnlineFirst:2016\/01\/02].","journal-title":"Atherosclerosis"},{"issue":"5","key":"2070_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/liv.14018[publishedOnlineFirst:2018\/12\/12]","volume":"39","author":"M Whitsett","year":"2019","unstructured":"Whitsett M, Wilcox J, Yang A, et al. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int. 2019;39(5):933\u201340. https:\/\/doi.org\/10.1111\/liv.14018[publishedOnlineFirst:2018\/12\/12].","journal-title":"Liver Int"},{"key":"2070_CR25","doi-asserted-by":"publisher","first-page":"5628749","DOI":"10.1155\/2018\/5628749[publishedOnlineFirst:2018\/08\/17]","volume":"2018","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Li P, Miao M, et al. Nonalcoholic fatty liver disease is associated with increased atrial fibrillation risk in an elderly Chinese population: a cross-sectional study. Biomed Res Int. 2018;2018:5628749. https:\/\/doi.org\/10.1155\/2018\/5628749[publishedOnlineFirst:2018\/08\/17].","journal-title":"Biomed Res Int"},{"key":"2070_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CLEP.S191914[publishedOnlineFirst:20190114]","volume":"11","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Lashkariani M. Cohort profile: ESPRESSO (epidemiology strengthened by histopathology reports in Sweden). Clin Epidemiol. 2019;11:101\u201314. https:\/\/doi.org\/10.2147\/CLEP.S191914[publishedOnlineFirst:20190114].","journal-title":"Clin Epidemiol"},{"key":"2070_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/CLEP.S90589[publishedOnlineFirst:20151123]","volume":"7","author":"JF Ludvigsson","year":"2015","unstructured":"Ludvigsson JF, Haberg SE, Knudsen GP, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol. 2015;7:491\u2013508. https:\/\/doi.org\/10.2147\/CLEP.S90589[publishedOnlineFirst:20151123].","journal-title":"Clin Epidemiol"},{"issue":"2","key":"2070_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y[publishedOnlineFirst:20160114]","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31(2):125\u201336. https:\/\/doi.org\/10.1007\/s10654-016-0117-y[publishedOnlineFirst:20160114].","journal-title":"Eur J Epidemiol"},{"key":"2070_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450[publishedOnlineFirst:20110609]","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. https:\/\/doi.org\/10.1186\/1471-2458-11-450[publishedOnlineFirst:20110609].","journal-title":"BMC Public Health"},{"issue":"2","key":"2070_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10654-009-9404-1[publishedOnlineFirst:2009\/11\/26]","volume":"25","author":"JG Smith","year":"2010","unstructured":"Smith JG, Platonov PG, Hedblad B, et al. Atrial fibrillation in the malmo diet and cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol. 2010;25(2):95\u2013102. https:\/\/doi.org\/10.1007\/s10654-009-9404-1[publishedOnlineFirst:2009\/11\/26].","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"2070_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/BF02598984[publishedOnlineFirst:1996\/12\/01]","volume":"11","author":"MR Antani","year":"1996","unstructured":"Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med. 1996;11(12):713\u201320. https:\/\/doi.org\/10.1007\/BF02598984[publishedOnlineFirst:1996\/12\/01].","journal-title":"J Gen Intern Med"},{"issue":"12","key":"2070_CR32","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1161\/01.str.28.12.2382[publishedOnlineFirst:1997\/12\/31]","volume":"28","author":"LM Brass","year":"1997","unstructured":"Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke. 1997;28(12):2382\u20139. https:\/\/doi.org\/10.1161\/01.str.28.12.2382[publishedOnlineFirst:1997\/12\/31].","journal-title":"Stroke"},{"issue":"2","key":"2070_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1053\/hj.1999.v137.91403[publishedOnlineFirst:1999\/01\/30]","volume":"137","author":"GC Flaker","year":"1999","unstructured":"Flaker GC, McGowan DJ, Boechler M, et al. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J. 1999;137(2):307\u201312. https:\/\/doi.org\/10.1053\/hj.1999.v137.91403[publishedOnlineFirst:1999\/01\/30].","journal-title":"Am Heart J"},{"issue":"10","key":"2070_CR34","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/STROKEAHA.107.508580[publishedOnlineFirst:2008\/07\/19]","volume":"39","author":"AY Shen","year":"2008","unstructured":"Shen AY, Yao JF, Brar SS, et al. Racial\/Ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39(10):2736\u201343. https:\/\/doi.org\/10.1161\/STROKEAHA.107.508580[publishedOnlineFirst:2008\/07\/19].","journal-title":"Stroke"},{"issue":"Suppl 1","key":"2070_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pds.2317[publishedOnlineFirst:2012\/01\/25]","volume":"21","author":"PN Jensen","year":"2012","unstructured":"Jensen PN, Johnson K, Floyd J, et al. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):141\u20137. https:\/\/doi.org\/10.1002\/pds.2317[publishedOnlineFirst:2012\/01\/25].","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2070_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8[publishedOnlineFirst:20190330]","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Svedberg P, Olen O, et al. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423\u201337. https:\/\/doi.org\/10.1007\/s10654-019-00511-8[publishedOnlineFirst:20190330].","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"2070_CR37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, et al. The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335. https:\/\/doi.org\/10.1002\/pds.1294.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2070_CR38","unstructured":"Rothman KJ, Greenland S, Lash TL. Modern Epidemiology: Wolters Kluwer Health\/Lippincott Williams & Wilkins 2015."},{"issue":"5","key":"2070_CR39","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/sim.6793[publishedOnlineFirst:2015\/12\/02]","volume":"35","author":"M Wang","year":"2016","unstructured":"Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35(5):782\u2013800. https:\/\/doi.org\/10.1002\/sim.6793[publishedOnlineFirst:2015\/12\/02].","journal-title":"Stat Med"},{"issue":"6","key":"2070_CR40","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"issue":"4","key":"2070_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607[publishedOnlineFirst:20170711]","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/M16-2607[publishedOnlineFirst:20170711].","journal-title":"Ann Intern Med"},{"issue":"2","key":"2070_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/liv.14236[publishedOnlineFirst:2019\/09\/04]","volume":"40","author":"JH Roh","year":"2020","unstructured":"Roh JH, Lee JH, Lee H, et al. Association between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults. Liver Int. 2020;40(2):338\u201346. https:\/\/doi.org\/10.1111\/liv.14236[publishedOnlineFirst:2019\/09\/04].","journal-title":"Liver Int"},{"issue":"4","key":"2070_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061803[publishedOnlineFirst:2013\/04\/30]","volume":"8","author":"YC Liu","year":"2013","unstructured":"Liu YC, Hung CS, Wu YW, et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS ONE. 2013;8(4): e61803. https:\/\/doi.org\/10.1371\/journal.pone.0061803[publishedOnlineFirst:2013\/04\/30].","journal-title":"PLoS ONE"},{"issue":"5","key":"2070_CR44","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/met.2016.0132[publishedOnlineFirst:2017\/03\/28]","volume":"15","author":"KI Cho","year":"2017","unstructured":"Cho KI, Jo EA, Cho SH, et al. The influence of epicardial fat and nonalcoholic fatty liver disease on heart rate recovery in metabolic syndrome. Metab Syndr Relat Disord. 2017;15(5):226\u201332. https:\/\/doi.org\/10.1089\/met.2016.0132[publishedOnlineFirst:2017\/03\/28].","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"2070_CR45","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jhep.2019.01.035[publishedOnlineFirst:2019\/02\/16]","volume":"70","author":"D Houghton","year":"2019","unstructured":"Houghton D, Zalewski P, Hallsworth K, et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol. 2019;70(6):1203\u201313. https:\/\/doi.org\/10.1016\/j.jhep.2019.01.035[publishedOnlineFirst:2019\/02\/16].","journal-title":"J Hepatol"},{"issue":"3","key":"2070_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0161734615595015[publishedOnlineFirst:2015\/07\/15]","volume":"38","author":"O Ozveren","year":"2016","unstructured":"Ozveren O, Izgi C, Eroglu E, et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty-liver disease. Ultrason Imaging. 2016;38(3):225\u201335. https:\/\/doi.org\/10.1177\/0161734615595015[publishedOnlineFirst:2015\/07\/15].","journal-title":"Ultrason Imaging"},{"issue":"12","key":"2070_CR47","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.numecd.2021.08.037[publishedOnlineFirst:2021\/10\/11]","volume":"31","author":"G Targher","year":"2021","unstructured":"Targher G, Mantovani A, Grander C, et al. Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic\/parasympathetic balance in subjects with and without type 2 diabetes-the cooperative health research in south tyrol (CHRIS)-NAFLD sub-study. Nutr Metab Cardiovasc Dis. 2021;31(12):3464\u201373. https:\/\/doi.org\/10.1016\/j.numecd.2021.08.037[publishedOnlineFirst:2021\/10\/11].","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"2070_CR48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0[publishedOnlineFirst:2018\/05\/02]","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):425\u201339. https:\/\/doi.org\/10.1038\/s41575-018-0010-0[publishedOnlineFirst:2018\/05\/02].","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"2070_CR49","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0[publishedOnlineFirst:2021\/05\/08]","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578\u201388. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0[publishedOnlineFirst:2021\/05\/08].","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2070_CR50","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.numecd.2014.01.005[publishedOnlineFirst:20140121]","volume":"24","author":"G Targher","year":"2014","unstructured":"Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014;24(6):663\u20139. https:\/\/doi.org\/10.1016\/j.numecd.2014.01.005[publishedOnlineFirst:20140121].","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"2070_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185459[publishedOnlineFirst:20171005]","volume":"12","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Rigolon R, Pichiri I, et al. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS ONE. 2017;12(10): e0185459. https:\/\/doi.org\/10.1371\/journal.pone.0185459[publishedOnlineFirst:20171005].","journal-title":"PLoS ONE"},{"issue":"10","key":"2070_CR52","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacep.2020.05.023[publishedOnlineFirst:2020\/10\/24]","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Cotter TG, Wazni OM, et al. Impact of nonalcoholic fatty liver disease on arrhythmia recurrence following atrial fibrillation ablation. JACC Clin Electrophysiol. 2020;6(10):1278\u201387. https:\/\/doi.org\/10.1016\/j.jacep.2020.05.023[publishedOnlineFirst:2020\/10\/24].","journal-title":"JACC Clin Electrophysiol"},{"key":"2070_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10590-1[publishedOnlineFirst:20230928]","author":"S Moller","year":"2023","unstructured":"Moller S, Wiese S, Barlose M, et al. How non-alcoholic fatty liver disease and cirrhosis affect the heart. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10590-1[publishedOnlineFirst:20230928].","journal-title":"Hepatol Int"},{"issue":"3","key":"2070_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jacep.2015.04.004[publishedOnlineFirst:2015\/06\/01]","volume":"1","author":"CX Wong","year":"2015","unstructured":"Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1(3):139\u201352. https:\/\/doi.org\/10.1016\/j.jacep.2015.04.004[publishedOnlineFirst:2015\/06\/01].","journal-title":"JACC Clin Electrophysiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-02070-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T10:05:23Z","timestamp":1702461923000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-02070-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-02070-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Board in Stockholm, Sweden (2014\/1287-31\/4, 2018\/972-32 and 2022-05774-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have completed the ICMJE uniform disclosure form at\n                      \n                      and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. TGS has received research funding from Amgen and has received consulting fees from Aetion, for work unrelated to this manuscript. FE has served as advisory board member for Boehringer Ingelheim. HH reports research grants to his institution from Astra Zeneca, Pfizer, Merck, EchoSens, Intercept and Gilead, and board advisory for Bristol-Myers Squibb and Gilead. JS reports ownership in companies providing services to Itrim, Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer, Bayer, Pfizer and AstraZeneca, outside the submitted work. JFL coordinates an unrelated study on behalf of the Swedish IBD quality register (SWIBREG), that has received funding from Janssen corporation. The remaining authors have no disclosures and no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"343"}}